Aavantibio Inc., with the help of a large check from Sarepta Therapeutics Inc., has launched with a $107 million series A to pursue gene therapies for treating rare genetic diseases. The lead program is in Friedreich’s ataxia (FA), a rare genetic disease that typically begins in childhood and causes progressive damage to the nervous system.

LONDON – Araris Biotech AG has raised CHF12.7 million (US$16.8 million) in a seed funding round to take forward what it claims is the holy grail for antibody-drug conjugates (ADCs), a linker technology that allows for the attachment of any payload to any antibody, without the need for engineering.

Med-tech firms raising money in public or private financings, including: Cricket Health, Enviral Tech, Helius Medical Technologies, Invivo Therapeutics Holdings, Neodynamics.

Biopharmas raising money in public or private financings, including: Aptinyx, Azura, Bellus, Galecto, Incarda, Replimune.

Med-tech firms raising money in public or private financings, including: Astrotech, Eargo, Loyal, Phreesia.

Biopharmas raising money in public or private financings, including: Aptinyx, C4X, FSD, Idorsia, Kiromic, Praxis, Regenerx, Replimune, Tarsus.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Aridis, IMV, Kanaph, Opthea.

Med-tech firms raising money in public or private financings, including: Cloudmd Software & Services, Diality, Medlite ID, Neuromod Devices, Stagezero Life Sciences.